Overview
The goal of this clinical trial is to evaluate the safety and efficacy of Baricitinib in the treatment of frontal fibrosing alopecia (FFA).
Eligibility
Inclusion Criteria:
- Female at least 18 years of age, and able to provide informed consent
- Females who are post-menopausal defined, as not have menses for at least 12 months without an alternative medical cause and elevated follicle stimulating hormone in the postmenopausal range as measured during screening
- Have active FFA that has been diagnosed on or prior to screening visit.
- Have LPPAI score equal to or greater than 5 at screening.
- Have evidence of eyebrow loss at baseline
- Have evidence of hairline recession at baseline
- Have classic presentation with frontal loss of scalp hair
- Negative screening for tuberculosis (Quantiferon Gold, T-spot) within 3 months prior to screening or at the screening visit.
- Agree not to have a live vaccination during the study the exception is herpes zoster vaccine
Exclusion Criteria:
- Systemic treatments for FFA within 4 weeks of the baseline visit or 5 half lives whichever one is longer. (ex: finasteride, pioglitazone, hydroxychloroquine, or immunosuppressant medications, such as mycophenolate mofetil).
- Dutasteride within the last 6 months
- Have a LPPAI score less than 5 at screening
- Immunocompromised and with risk factors concerning to investigator for study participation
- Previous treatment with an oral JAK inhibitor
- Any condition in the opinion of the investigator which would interfere with the study assessments or procedure
- Subject is pregnant or breast feeding
- Surgical intervention including face lifts and micro-blading on the treatment areas
- Any intervention (facelifts micro blading) that could affect the treatment areas (i.e. scalp and eyebrows)
- Laser or phototherapy intervention on the treatment areas
- Have evidence of active TB or latent TB